share_log

Innate Pharma's TELLOMAK Phase 2 Trial: Lacutamab Demonstrates Significant Symptom Relief and Quality-of-Life Improvements In Advanced CTCL, Presented At ASH 2024

Innate Pharma's TELLOMAK Phase 2 Trial: Lacutamab Demonstrates Significant Symptom Relief and Quality-of-Life Improvements In Advanced CTCL, Presented At ASH 2024

innate pharma的TELLOMAk II期试验:Lacutamab在爱文思控股晚期CTCL中显示出显著的症状缓解和生活质量改善,已在2024年ASH大会上展示。
Benzinga ·  2024/12/09 15:07
  • Findings reveal promising early signs that lacutamab may help alleviate some of the most distressing symptoms of cutaneous T cell lymphomas
  • 研究结果揭示了Lacutamab可能有助于缓解部分皮肤T细胞淋巴瘤患者最痛苦症状的早期良好迹象。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发